PURPOSE: DNA adduct levels may be influenced by metabolic activity, DNA repair capabilities, and genomic integrity, all of which play a role in cancer progression. EXPERIMENTAL DESIGN: To determine if elevated DNA adducts are a marker for prostate cancer progression, we measured polycyclic aromatic hydrocarbon-DNA adducts by immunohistochemistry in prostate cells of 368 surgical prostate cancer patients treated at the Henry Ford Hospital in Detroit, Michigan, between September 1999 and July 2004. Patients were followed up to 5 years after surgery with relative risk for biochemical recurrence (BCR) estimated with a Cox proportional hazards model that adjusted for standard clinical risk factors. RESULTS: At 1 year of follow-up, patients with adduct levels above the median in tumor cells [hazard ratio (HR), 2.40; 95% confidence interval (95% CI), 1.10-5.27] and nontumor cells (HR, 3.22; 95% CI, 1.40-7.39) had significant increased risk of BCR, but these HRs decreased to 1.12 (95% CI, 0.68-1.83) and 1.46 (95% CI, 0.89-2.41) in tumor and nontumor cells at 5 years postsurgery. When we restricted our analysis to patients with advanced-stage (III+) disease, those with high adduct levels in either tumor (53.5% versus 30.2%; P = 0.07) or nontumor (55.2% versus 28.6%; P = 0.02) cells had BCR rates almost 2-fold higher. In race-stratified analyses, the greatest risk of BCR associated with high adduct levels (in nontumor cells) was for African American patients younger than 60 years old (HR, 3.79; 95% CI, 1.01-14.30). CONCLUSIONS: High polycyclic aromatic hydrocarbon-DNA adduct levels in nontumor prostate cells are most strongly associated with BCR between 1 and 2 years after surgery and in patient subsets defined by younger age, advanced tumor stage, and African American race.
PURPOSE: DNA adduct levels may be influenced by metabolic activity, DNA repair capabilities, and genomic integrity, all of which play a role in cancer progression. EXPERIMENTAL DESIGN: To determine if elevated DNA adducts are a marker for prostate cancer progression, we measured polycyclic aromatic hydrocarbon-DNA adducts by immunohistochemistry in prostate cells of 368 surgical prostate cancerpatients treated at the Henry Ford Hospital in Detroit, Michigan, between September 1999 and July 2004. Patients were followed up to 5 years after surgery with relative risk for biochemical recurrence (BCR) estimated with a Cox proportional hazards model that adjusted for standard clinical risk factors. RESULTS: At 1 year of follow-up, patients with adduct levels above the median in tumor cells [hazard ratio (HR), 2.40; 95% confidence interval (95% CI), 1.10-5.27] and nontumor cells (HR, 3.22; 95% CI, 1.40-7.39) had significant increased risk of BCR, but these HRs decreased to 1.12 (95% CI, 0.68-1.83) and 1.46 (95% CI, 0.89-2.41) in tumor and nontumor cells at 5 years postsurgery. When we restricted our analysis to patients with advanced-stage (III+) disease, those with high adduct levels in either tumor (53.5% versus 30.2%; P = 0.07) or nontumor (55.2% versus 28.6%; P = 0.02) cells had BCR rates almost 2-fold higher. In race-stratified analyses, the greatest risk of BCR associated with high adduct levels (in nontumor cells) was for African American patients younger than 60 years old (HR, 3.79; 95% CI, 1.01-14.30). CONCLUSIONS: High polycyclic aromatic hydrocarbon-DNA adduct levels in nontumor prostate cells are most strongly associated with BCR between 1 and 2 years after surgery and in patient subsets defined by younger age, advanced tumor stage, and African American race.
Authors: Marilie D Gammon; Regina M Santella; Alfred I Neugut; Sybil M Eng; Susan L Teitelbaum; Andrea Paykin; Bruce Levin; Mary Beth Terry; Tie Lan Young; Lian Wen Wang; Qiao Wang; Julie A Britton; Mary S Wolff; Steven D Stellman; Maureen Hatch; Geoffrey C Kabat; Ruby Senie; Gail Garbowski; Carla Maffeo; Pat Montalvan; Gertrud Berkowitz; Margaret Kemeny; Marc Citron; Freya Schnabel; Allan Schuss; Steven Hajdu; Vincent Vinceguerra Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-08 Impact factor: 4.254
Authors: Rong Fan; Tirukalikundram S Kumaravel; Farid Jalali; Paula Marrano; Jeremy A Squire; Robert G Bristow Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: G Romano; A Sgambato; A Boninsegna; G Flamini; G Curigliano; Q Yang; V La Gioia; C Signorelli; A Ferro; G Capelli; R M Santella; A Cittadini Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-01 Impact factor: 4.254
Authors: Jennifer J Hu; M Craig Hall; Lawrence Grossman; Mohammad Hedayati; David L McCullough; Kurt Lohman; L Douglas Case Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Nora L Nock; Deliang Tang; Andrew Rundle; Christine Neslund-Dudas; Adnan T Savera; Cathryn H Bock; Kristin G Monaghan; Allison Koprowski; Nicoleta Mitrache; James J Yang; Benjamin A Rybicki Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: Nora L Nock; Cathryn Bock; Christine Neslund-Dudas; Jennifer Beebe-Dimmer; Andrew Rundle; Deliang Tang; Michelle Jankowski; Benjamin A Rybicki Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506
Authors: Christine M Neslund-Dudas; Russell B McBride; Ashoka Kandegedara; Benjamin A Rybicki; Oleksandr N Kryvenko; Dhananjay Chitale; Nilesh Gupta; Sean R Williamson; Craig G Rogers; Carlos Cordon-Cardo; Andrew G Rundle; Albert M Levin; Q Ping Dou; Bharati Mitra Journal: J Trace Elem Med Biol Date: 2018-04-13 Impact factor: 3.849
Authors: Jaclyn M Goodrich; Melissa A Furlong; Alberto J Caban-Martinez; Alesia M Jung; Ken Batai; Timothy Jenkins; Shawn Beitel; Sally Littau; John Gulotta; Darin Wallentine; Jeff Hughes; Charles Popp; Miriam M Calkins; Jefferey L Burgess Journal: Epigenet Insights Date: 2021-03-26
Authors: Kaarthik John; Narasimhan Ragavan; M Margaret Pratt; Paras B Singh; Salah Al-Buheissi; Shyam S Matanhelia; David H Phillips; Miriam C Poirier; Francis L Martin Journal: Prostate Date: 2009-04-01 Impact factor: 4.104